Gut Microbiome, Short-Chain Fatty Acids, and Mucosa Injury in Young Adults with Human Immunodeficiency Virus Infection

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2018 Dec 19

PMID 30560340

Citations 30

Authors

Yong Qing

Hangyu Xie

Chen Su

Youwei Wang

Qiuyue Yu

Qiuyu Pang

Fan Cui

Affiliations

Soon will be listed here.

Abstract

Background: HIV progression is characterized by immune activation and microbial translocation from the gut. Short-chain fatty acids (SCFAs) are essential for gut homeostasis. Decreased intestinal SCFAs play a role in rapid HIV progression.

Aims: To compare the SCFA profile, intestinal microbiome, and intestinal mucosal injury between patients with HIV (but not AIDS) and healthy controls.

Methods: This was a prospective study of 15 patients without AIDS and 10 controls conducted between July 2016 and January 2017 at the Institute of Dermatology and Venereology (Sichuan Academy of Medical Sciences). Stool specimens were collected to analyze the microbiome and SCFAs. Blood I-FABP and D-lactate (gut injury markers) were measured as well as T cells in HIV-positive patients. Intestinal mucosa was observed by colonoscopy.

Results: Rikenellaceae, Microbacteriaceae, Roseburia, Lachnospiraceae, Alistipes, and Ruminococcaceae were decreased, while Moraxellaceae and Psychrobacter were increased in HIV-positive patients. Butyric acid (p = 0.04) and valeric acid (p = 0.03) were reduced in HIV-positive patients. Colonoscopy revealed no visible damage in all subjects. There were no differences in I-FABP and D-lactate between groups. Butyric and valeric acids mainly positively correlated with Rikenellaceae, Ruminococcaceae, Alistipes, Roseburia, and Lachnospiraceae. CD8+ cells were positively correlated with Proteobacteria. CD4+ cells, and CD4/CD8 were negatively correlated with acetic acid. CD8+ cells were positively correlated with valeric acid.

Conclusion: The differences in the distribution of intestinal flora between HIV-infected and healthy individuals, especially some SCFAs, suggest that there is already a predisposition to intestinal mucosa damage in HIV-infected individuals.

Citing Articles

Alterations of the Intestinal Mucosal Barrier and Gut Fungal Microbiome in Asymptomatic HIV-Infected Patients.

Li W, Qing Y, Yu Q, Zhang H, Rang Z, Li S Can J Infect Dis Med Microbiol. 2025; 2024:6995192.

PMID: 39886072 PMC: 11779998. DOI: 10.1155/cjid/6995192.

Changes in Type 1 Diabetes-Associated Gut Microbiota Aggravate Brain Ischemia Injury by Affecting Microglial Polarization Via the Butyrate-MyD88 Pathway in Mice.

Zeng X, Ma C, Fu W, Xu Y, Wang R, Liu D Mol Neurobiol. 2024; 62(3):3764-3780.

PMID: 39322832 DOI: 10.1007/s12035-024-04514-9.

Intestinal and hepatic benefits of BBR-EVO on DSS-induced experimental colitis in mice.

Wang W, Han Y, Yin W, Wang Q, Wu Y, Du M Front Microbiol. 2024; 15:1428327.

PMID: 39296302 PMC: 11408294. DOI: 10.3389/fmicb.2024.1428327.

HIV-associated neurocognitive disorder: key implications of the microbiota-gut-brain axis.

Hu A, Zaongo S, Harypursat V, Wang X, Ouyang J, Chen Y Front Microbiol. 2024; 15:1428239.

PMID: 39155987 PMC: 11327151. DOI: 10.3389/fmicb.2024.1428239.

Dietary copper improves intestinal structural integrity in juvenile grass carp () probably related to its increased intestinal antioxidant capacity and apical junction complex.

Ma R, Feng L, Wu P, Liu Y, Ren H, Jin X Anim Nutr. 2024; 18:96-106.

PMID: 39056059 PMC: 11269860. DOI: 10.1016/j.aninu.2024.02.005.

References

Feinberg J . In the clinic. Management of newly diagnosed HIV infection. Ann Intern Med. 2011; 155(7):ITC41. DOI: 10.7326/0003-4819-155-7-201110040-01004. View

Cohen M, Shaw G, McMichael A, Haynes B . Acute HIV-1 Infection. N Engl J Med. 2011; 364(20):1943-54. PMC: 3771113. DOI: 10.1056/NEJMra1011874. View

Wilcox C, Saag M . Gastrointestinal complications of HIV infection: changing priorities in the HAART era. Gut. 2008; 57(6):861-70. DOI: 10.1136/gut.2006.103432. View

Li S, Armstrong A, Neff C, Shaffer M, Lozupone C, Palmer B . Complexities of Gut Microbiome Dysbiosis in the Context of HIV Infection and Antiretroviral Therapy. Clin Pharmacol Ther. 2016; 99(6):600-11. PMC: 4927263. DOI: 10.1002/cpt.363. View

Chevalier M, Petitjean G, Dunyach-Remy C, Didier C, Girard P, Manea M . The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation. PLoS Pathog. 2013; 9(6):e1003453. PMC: 3688532. DOI: 10.1371/journal.ppat.1003453. View

Gori A, Tincati C, Rizzardini G, Torti C, Quirino T, Haarman M . Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis. J Clin Microbiol. 2007; 46(2):757-8. PMC: 2238068. DOI: 10.1128/JCM.01729-07. View

Tincati C, Douek D, Marchetti G . Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection. AIDS Res Ther. 2016; 13:19. PMC: 4828806. DOI: 10.1186/s12981-016-0103-1. View

Burgener A, McGowan I, Klatt N . HIV and mucosal barrier interactions: consequences for transmission and pathogenesis. Curr Opin Immunol. 2015; 36:22-30. DOI: 10.1016/j.coi.2015.06.004. View

Noguera-Julian M, Rocafort M, Guillen Y, Rivera J, Casadella M, Nowak P . Gut Microbiota Linked to Sexual Preference and HIV Infection. EBioMedicine. 2016; 5:135-46. PMC: 4816837. DOI: 10.1016/j.ebiom.2016.01.032. View

10.

Dillon S, Kibbie J, Lee E, Guo K, Santiago M, Austin G . Low abundance of colonic butyrate-producing bacteria in HIV infection is associated with microbial translocation and immune activation. AIDS. 2016; 31(4):511-521. PMC: 5263163. DOI: 10.1097/QAD.0000000000001366. View

11.

Nowak P, Troseid M, Avershina E, Barqasho B, Neogi U, Holm K . Gut microbiota diversity predicts immune status in HIV-1 infection. AIDS. 2015; 29(18):2409-18. DOI: 10.1097/QAD.0000000000000869. View

12.

Zilberman-Schapira G, Zmora N, Itav S, Bashiardes S, Elinav H, Elinav E . The gut microbiome in human immunodeficiency virus infection. BMC Med. 2016; 14(1):83. PMC: 4891875. DOI: 10.1186/s12916-016-0625-3. View

13.

Mutlu E, Keshavarzian A, Losurdo J, Swanson G, Siewe B, Forsyth C . A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog. 2014; 10(2):e1003829. PMC: 3930561. DOI: 10.1371/journal.ppat.1003829. View

14.

Saxena D, Li Y, Devota A, Pushalkar S, Abrams W, Barber C . Modulation of the orodigestive tract microbiome in HIV-infected patients. Oral Dis. 2016; 22 Suppl 1:73-8. DOI: 10.1111/odi.12392. View

15.

Serrano-Villar S, Rojo D, Martinez-Martinez M, Deusch S, Vazquez-Castellanos J, Bargiela R . Gut Bacteria Metabolism Impacts Immune Recovery in HIV-infected Individuals. EBioMedicine. 2016; 8:203-216. PMC: 4919658. DOI: 10.1016/j.ebiom.2016.04.033. View

16.

Tao J, Duan J, Jiang S, Guo J, Qian Y, Qian D . Simultaneous determination of six short-chain fatty acids in colonic contents of colitis mice after oral administration of polysaccharides from Chrysanthemum morifolium Ramat by gas chromatography with flame ionization detector. J Chromatogr B Analyt Technol Biomed Life Sci. 2016; 1029-1030:88-94. DOI: 10.1016/j.jchromb.2016.07.002. View

17.

Das B, Dobrowolski C, Shahir A, Feng Z, Yu X, Sha J . Short chain fatty acids potently induce latent HIV-1 in T-cells by activating P-TEFb and multiple histone modifications. Virology. 2014; 474:65-81. PMC: 4259832. DOI: 10.1016/j.virol.2014.10.033. View

18.

Kelly C, Zheng L, Campbell E, Saeedi B, Scholz C, Bayless A . Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function. Cell Host Microbe. 2015; 17(5):662-71. PMC: 4433427. DOI: 10.1016/j.chom.2015.03.005. View

19.

Kim C, Park J, Kim M . Gut microbiota-derived short-chain Fatty acids, T cells, and inflammation. Immune Netw. 2015; 14(6):277-88. PMC: 4275385. DOI: 10.4110/in.2014.14.6.277. View

20.

Yuille S, Reichardt N, Panda S, Dunbar H, Mulder I . Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid. PLoS One. 2018; 13(7):e0201073. PMC: 6063406. DOI: 10.1371/journal.pone.0201073. View